Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data by Eichler, Hermann et al.
60  |    Haemophilia. 2019;25:60–66.wileyonlinelibrary.com/journal/hae
 
Received: 22 June 2018  |  Revised: 4 October 2018  |  Accepted: 4 October 2018
DOI: 10.1111/hae.13627
O R I G I N A L  A R T I C L E
Clinical haemophilia
Concizumab restores thrombin generation potential in patients 
with haemophilia: Pharmacokinetic/pharmacodynamic 
modelling results of concizumab phase 1/1b data
Hermann Eichler1  | Pantep Angchaisuksiri2 | Kaan Kavakli3  | Paul Knoebl4 | Jerzy 
Windyga5  | Victor Jiménez‐Yuste6 | Philip Harder Delff7 | Pratima Chowdary8
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
© 2018 The Authors. Haemophilia Published by John Wiley & Sons Ltd.
1Institute of Clinical Hemostaseology and 
Transfusion Medicine, Saarland University 
and University Hospital, Homburg/Saar, 
Germany
2Division of Hematology, Department of 
Medicine, Ramathibodi Hospital, Mahidol 
University, Bangkok, Thailand
3Department of Hematology, Ege University 
Children’s Hospital, Izmir, Turkey
4Clinical Division of Hematology and 
Hemostasis, Medical University of Vienna, 
Vienna, Austria
5Department of Disorders of Hemostasis 
and Internal Medicine, Institute of 
Hematology and Transfusion Medicine, 
Warsaw, Poland
6Haematology Department, La Paz 
University Hospital, Madrid, Spain
7Novo Nordisk A/S, Copenhagen, Denmark
8Katharine Dormandy Haemophilia Centre 
and Thrombosis Unit, Royal Free London 
NHS Foundation Trust, London, UK
Correspondence
Hermann Eichler, Institute of Clinical 
Hemostaseology and Transfusion Medicine, 
Saarland University and University Hospital, 
Homburg/Saar, Germany.
Email: hermann.eichler@uks.eu
Funding information
Novo Nordisk
Introduction: Concizumab enhances thrombin generation (TG) potential in haemo‐
philia patients by inhibiting tissue factor pathway inhibitor (TFPI). In EXPLORER3 
(phase 1b), a dose‐dependent pharmacokinetic/pharmacodynamic (PK/PD) relation‐
ship was confirmed between concizumab dose, free TFPI and TG potential.
Aim: Determine the association between concizumab exposure, PD markers (free 
TFPI; peak TG) and bleeding episodes to establish the minimum concizumab concen‐
tration for achieving sufficient efficacy.
Methods: Free TFPI predictions were generated using an estimated concizumab‐free 
TFPI exposure‐response (Emax) model based on concizumab phase 1/1b data for which 
simultaneously collected concizumab and free TFPI samples were available. Concizumab 
concentration at the time of a bleed was predicted using a PK model, based on available 
data for concizumab doses >50 μg/kg to ≤9 mg/kg. Peak TG vs concizumab concentra‐
tion analyses and an Emax model were constructed based on EXPLORER3 observations.
Results: The Emax model showed a tight PK/PD relationship between concizumab 
exposure and free TFPI; free TFPI decreased with increasing concizumab concentra‐
tion. A strong correlation between concizumab concentration and peak TG was ob‐
served; concizumab >100 ng/mL re‐established TG potential to within the normal 
reference range. Estimated EC50 values for the identified concizumab‐free TFPI and 
concizumab‐TG potential models were very similar, supporting free TFPI as an impor‐
tant biomarker. A correlation between bleeding episode frequency and concizumab 
concentration was indicated; patients with a concizumab concentration >100 ng/mL 
experienced less frequent bleeding. The PK model predicted that once‐daily dosing 
would minimize within‐patient concizumab PK variability.
Conclusion: Concizumab phase 2 trials will target an exposure ≥100 ng/mL, with a 
once‐daily regimen.
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1  | INTRODUC TION
Several novel therapeutic avenues are being explored with the aim 
of improving management strategies for people with haemophilia, 
including gene therapy approaches, RNA interference, factor VIII 
(FVIII) mimetics and blockade of tissue factor pathway inhibitor 
(TFPI). Although primary prophylaxis is considered optimal for peo‐
ple with severe haemophilia,1 significant barriers to the efficient 
implementation of prophylaxis persist. These barriers include the 
development of inhibitors, which are neutralizing antibodies formed 
against allogeneic factor VIII (FVIII) or factor IX (FIX), resulting in the 
reduction or elimination of FVIII/FIX activity and ultimately leading 
to a suboptimal response to treatment, increased disease burden 
and morbidity, and reduced quality of life.2‐4 A further barrier is the 
need for intravenous (iv) injections, which are painful, time‐consum‐
ing and require venous access that can be difficult to achieve, partic‐
ularly in young children.5,6
Concizumab is among the novel therapeutics in clinical devel‐
opment for the treatment of haemophilia and is a potentially first‐
in‐class TFPI inhibitor. It is a humanized, recombinant monoclonal 
antibody (mAb) that binds with high affinity to the Kunitz‐2 domain 
of TFPI. TFPI plays a crucial role in controlling coagulation by acting 
as the primary regulator of the initiation phase of normal coagu‐
lation. Following vessel wall injury, the tissue factor (TF)‐activated 
factor VII (FVIIa) complex is formed and activates FIX to FIXa and 
factor X (FX) to FXa. TFPI binds to and inhibits FXa (via its Kunitz‐2 
domain), followed by binding to FVIIa in the TF‐FVIIa complex (via 
its Kunitz‐1 domain), “turning off” the initiation phase of coagulation 
and ultimately resulting in the inhibition of thrombin generation. In 
normal coagulation, following inhibition of the initiation phase, FX 
activation and thrombin generation is ensured via the action of the 
intrinsic tenase complex (activated factor VIII [FVIIIa]‐FIXa com‐
plex) during the propagation phase. People with haemophilia have 
impaired propagation due to reduced FVIII/FIX levels, leading to 
reduced FXa generation and increased bleeding. By inhibiting TFPI, 
concizumab prevents inhibition of not only FXa but also of the TF‐
FVIIa complex, thereby leading to ongoing FXa generation in the 
presence of tissue injury and subsequent activation of the remain‐
ing steps of the common coagulation pathway cascade, ultimately 
resulting in a thrombin “burst” even in the absence of functional 
FVIII (haemophilia A patients) or FIX (haemophilia B patients) or 
the presence of inhibitors.7‐10 Concizumab is therefore being devel‐
oped for the prevention of bleeding episodes, including long‐term 
prophylaxis, in patients with haemophilia A and B with or without 
inhibitors. As it is a mAb, concizumab allows subcutaneous (sc) ad‐
ministration, and as it exhibits good solubility and stability, it can be 
formulated as a liquid for use in a ready‐ and easy‐to‐use portable 
pen device.11
In EXPLORER1 (ClinicalTrials.gov identifier: NCT01228669), a 
first‐in‐human trial, concizumab exhibited a favourable safety pro‐
file following a single sc or iv dose administered to healthy volun‐
teers or patients with haemophilia A or B. There were no serious 
adverse events and no anti‐concizumab antibodies were reported. 
In addition, a dose‐dependent, pro‐coagulant effect was observed, 
as well as a non‐linear pharmacokinetic (PK) profile as a result of 
target‐mediated clearance.12 EXPLORER3 (NCT02490787) was a 
phase 1b, double‐blind, multiple‐dose escalation trial of sc conci‐
zumab in patients with severe haemophilia A without inhibitors. 
In the primary analysis of EXPLORER3, no serious adverse events 
were seen in the completed cohorts, and a PK/pharmacodynamic 
(PD) relationship for concizumab dose, free TFPI and thrombin 
generation was confirmed.13 Currently, concizumab is being as‐
sessed in phase 2 clinical trials in patients with severe haemophilia 
A without inhibitors (EXPLORER5; NCT03196297), as well as in 
patients with haemophilia A or B with inhibitors (EXPLORER4; 
NCT03196284).
Here, we present results from exploratory PK/PD analyses of 
data from concizumab phase 1/1b trials, which aimed to determine 
the association between concizumab exposure and the PD markers 
free TFPI and peak thrombin generation. Although the EXPLORER3 
trial was not sufficiently powered to establish a prophylactic effect 
in terms of bleeding, the reported bleeding episodes from the trial 
were also included in the analyses. Through these analyses, we 
aimed to confirm the mechanism of action of concizumab by show‐
ing a decrease in free TFPI, expected to be accompanied by an in‐
crease in coagulation (seen as an increase in thrombin generation 
potential), and ultimately reflected clinically as a reduction in the 
number of bleeding episodes. The PK/PD analyses presented herein 
guided the design of the concizumab phase 2 studies, specifically in 
terms of dose setting.
2  | MATERIAL S AND METHODS
2.1 | Concizumab dosing in phase 1/1b clinical trials
Data from 4 trials involving 48 patients with haemophilia A/B and 40 
healthy volunteers were included in the PK/PD analyses presented 
herein: 21 and 3 patients with haemophilia A and B, respectively, and 
28 healthy volunteers from EXPLORER1; four and eight healthy vol‐
unteers from EXPLORER2 and the Japanese trial, respectively; and 
24 patients with haemophilia A from EXPLORER3. In EXPLORER1, a 
phase 1, multicentre, randomized, double‐blind, placebo‐controlled 
trial, single, escalating, iv (0.0005‐9 mg/kg) or sc (0.05‐3 mg/kg) 
doses of concizumab were administered to healthy volunteers and 
patients with haemophilia A or B.12 In EXPLORER2 (NCT01631942), 
a multicentre, open‐labelled, multiple‐dose trial, healthy volun‐
teers received eight consecutive sc concizumab doses (0.25 mg/kg) 
every other day. In a study that assessed concizumab PK in healthy 
Japanese volunteers (NCT01555749), a randomized, double‐blind, 
placebo‐controlled, single‐centre trial, single sc concizumab doses 
of 0.25 and 1.0 mg/kg were administered. In EXPLORER3, five es‐
calating dose levels of sc concizumab (0.25, 0.5, 0.8, 1.1 and 1.5 mg/
kg) were planned, but the trial was finalized after completion of the 
0.8 mg/kg cohort based on coagulation and PK parameter changes 
that were observed in the 0.8 mg/kg cohort, as well as the high inter‐
patient variation in the PK parameters and pro‐coagulant response 
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to concizumab in this cohort. No serious adverse events were ob‐
served in the completed dose groups.13 Each patient in EXPLORER3 
received the first two doses on two consecutive days to allow steady 
state to be reached rapidly, followed by subsequent administration 
once every 4 days.
All concizumab trials were conducted in accordance with the 
Declaration of Helsinki and ICH Good Clinical Practice guidelines. 
The trials were approved by the relevant ethics committees or in‐
stitutional review boards. Written signed informed consent was ob‐
tained from all participants.
2.2 | Concizumab population PK model
A PK model was constructed based on all available iv and sc clini‐
cal data for concizumab doses >0.05 mg/kg and up to 9 mg/kg 
(data from 42 patients and 13 healthy volunteers). Data were best 
described by a two‐compartmental model with both a linear and 
non‐linear clearance component. Classical disposition parameters 
(clearance [CL], central volume of distribution [V1], peripheral vol‐
ume of distribution [V2] and inter‐compartmental clearance [Q]) 
were comparable to those reported for other mAbs.14 As the maxi‐
mum elimination rate of the Michaelis Menten component (Vmax) 
related to target‐mediated clearance is high, the total clearance for 
low concentrations was estimated to be ~100‐fold higher than at 
full saturation of the target. Variability simulations were performed 
by using individually estimated parameters, and by repeating inter‐
occasion variability components as estimated within patients. A 
detailed description of the PK model is provided in a separate manu‐
script (in preparation).
2.3 | Concizumab PK/PD modelling
2.3.1 | Concizumab exposure‐free TFPI Emax model
An estimated exposure‐response (Emax) model, based on all conci‐
zumab phase 1/1b data for which simultaneously collected conci‐
zumab and free TFPI samples were available, was constructed to 
determine the relationship between concizumab concentration and 
the affinity to its target (ie, TFPI) (Figure 1). A basic assumption in 
this approach is that the effect of concizumab on free TFPI concen‐
tration is in steady state and is based on the half‐life of concizumab 
being much larger than the half‐life of TFPI.12,15 All pre‐dose sam‐
ples from EXPLORER1 patients treated with concizumab iv were 
excluded from the analysis as some of them had been spiked with 
concizumab prior to the analysis. Sigmoidal Emax models with be‐
tween‐subject variability on baseline and half‐maximal effective 
concentration (EC50) and covariates on baseline and EC50 were in‐
vestigated. Both statistical tests and visual inspection of goodness‐
of‐fit were used for decisions on model structure. Terms were only 
considered if they were judged to be pharmacologically meaningful. 
Likelihood ratio tests at 5% significance level were used throughout.
The sigmoidal Emax model of the free TFPI concentration pre‐
dicted by the concizumab concentration was designed as an Emax 
model of free TFPI reduction from baseline (at zero concizumab 
concentration). Full reduction resulted in a free TFPI concentra‐
tion at the lower limit of quantification (LLOQ). TFPI LLOQ var‐
ied between trials (12.5 ng/mL for EXPLORER1 and the Japanese 
trial, and 17.0 and 9.6 ng/mL for EXPLORER2 and EXPLORER3, 
respectively). The model was developed in a stepwise fashion. 
First, the model structure (non‐sigmoidal vs sigmoidal) and resid‐
ual error model (additive, proportional, or combined) were tested. 
Then, subject‐level random effects were included and, finally, 
covariates were sequentially included based on likelihood ratio 
testing. Trial effects were tested on the model‐predicted baseline 
free TFPI concentration. The effect of each individual trial, as well 
as of different trial groupings was assessed. The effect of Asian 
vs non‐Asian ethnicity was tested on both model‐predicted base‐
line and EC50. The effect of healthy volunteers vs haemophilia (A 
and B) patients was tested on model‐predicted baseline, but not 
on EC50, as the doses in the two groups were too unbalanced, 
with healthy volunteers receiving doses up to 0.25 mg/kg (except 
for six subjects receiving 1 mg/kg sc). When no more covariates 
were significant, all included terms were tested separately and al‐
ternative residual error models (proportional and additive) were 
retested.
2.3.2 | Concizumab exposure‐thrombin generation 
potential association
Analyses of peak thrombin generation vs concizumab concentra‐
tions were constructed based on observations in the EXPLORER3 
trial (data from 24 patients). A sigmoidal Emax model of the logarithm 
of peak thrombin generation was fitted with concizumab concentra‐
tion as explanatory variable.
F I G U R E  1   Concizumab concentration and free tissue factor 
pathway inhibitor (TFPI) observations. Concizumab phase 1/1b 
data used to build an estimated exposure‐response (Emax) model for 
concizumab‐free TFPI are shown. The lower limit of quantification 
values varied between trials. Free TFPI values were generally 
higher in EXPLORER2 and EXPLORER3 than in EXPLORER1 and 
the Japanese trial. This was observed in both placebo and pre‐dose 
samples, as well as in post‐dose samples. This observation was 
included as a baseline fixed effect in the concizumab exposure‐free 
TFPI model
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2.3.3 | Concizumab exposure‐free TFPI association 
at bleeding episodes
Concizumab concentration at the time of a bleeding episode 
in EXPLORER3 was predicted using the population PK model. 
Predictions of free TFPI at the time of bleeds were then gener‐
ated using the concizumab‐free TFPI Emax model. A total of 106 
bleeding episodes were included in the analysis; 91 bleeding epi‐
sodes recorded in 21 patients (of whom 5 were on placebo) during 
EXPLORER3,13 and 15 treated bleeds that occurred prior to initia‐
tion of dosing.
3  | RESULTS
3.1 | Concizumab exposure‐free TFPI association
A sigmoidal model with proportional error was chosen for the 
concizumab‐free TFPI Emax model. A sigmoidal Emax relationship 
was identified between concizumab concentration and reduction 
of free TFPI in plasma, with a significant sigmoidal Hill coefficient 
(1.75 [95% confidence interval: 1.47‐2.03]) (Table 1). Subject‐level 
random effects were significant on both baseline free TFPI con‐
centration and EC50. The trial effect leading to the smallest P‐value 
was obtained by grouping EXPLORER1 with the Japanese trial data 
and the EXPLORER2 with EXPLORER3 data. It was observed that 
the random effect on EC50 led to very large EC50 values for two of 
the three patients receiving 9 mg/kg iv. As 9 mg/kg is considerably 
higher than the concizumab doses administered to patients in clini‐
cal trials, it was decided to test the effect of this dose level on EC50 
in order for these observations not to have too large an influence on 
the EC50 estimate for a typical subject. The estimated typical value 
for EC50 was 62 ng/mL. The combined trial effect of EXPLORER1 
and the Japanese study was significant on model‐predicted baseline 
TFPI concentration, while data for concizumab 9 mg/kg iv had a sig‐
nificant effect on EC50.
In data described by the Emax model, a tight PK/PD relationship 
was observed between concizumab exposure and free TFPI, with 
free TFPI decreasing with increasing concizumab concentration 
(Figure 2). A similar TFPI baseline distribution (at zero concizumab 
concentration) was predicted for patients receiving placebo and for 
pre‐dose samples.
TA B L E  1   Concizumab‐free TFPI exposure‐response model parameter estimates
Estimate 95% CI (lower) 95% CI (upper)
Relative 
standard 
error (%)
Between‐subject 
variability (% CV) Shrinkage (%)
Baseline (ng/mL) 81.5 75.4 87.5 3.77 19.5 10.2
EC50 (ng/mL) 62.2 52.4 72 8.02 62.6 21.3
Hill coefficient 1.75 1.47 2.03 8.05 NA NA
EXPLORER1/Japanese trial (effect 
on baseline)
0.742 0.676 0.808 4.51 NA NA
Concizumab 9 mg/kg iv (effect on 
EC50)
11.1 8.61 13.5 11.3 NA NA
Proportional error (% CV) 22.1 NA NA NA NA 4.0311
NA, not applicable; TFPI, tissue factor pathway inhibitor.
The model was based on all concizumab phase 1/1b data for which simultaneously collected concizumab and free TFPI samples were available.
F I G U R E  2   Relationship between concizumab exposure, free 
tissue factor pathway inhibitor (TFPI) and bleeding episodes. 
Estimated exposure‐response (Emax) model of free TFPI predictions 
based on all concizumab phase 1/1b data for which simultaneously 
collected concizumab and free TFPI samples were available are 
shown. Free TFPI predictions relative to the predicted baseline 
free TFPI concentration vs observed concizumab concentration 
are shown. At bleeding events in EXPLORER3 (red dots), 
concizumab concentration was predicted using a population 
pharmacokinetic model (based on all available intravenous and 
subcutaneous clinical data for concizumab doses >0.05 mg/kg and 
up to 9 mg/kg) and, subsequently, free TFPI concentration was 
predicted using a concizumab−free TFPI Emax model. The solid line 
represents predictions of free TFPI concentration vs concizumab 
concentration for a typical subject. A typical subject was defined 
as a subject from EXPLORER2 or EXPLORER3 with typical baseline 
TFPI concentration and EC50 value. Jitter has been added to free 
TFPI levels for bleeds at predicted PK levels below 10 ng/mL in 
order to distinguish points graphically. The same has been done 
to observations at full reduction of free TFPI. Predictions are not 
shown for concizumab 9 mg/kg
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3.2 | Concizumab exposure‐thrombin generation 
potential association
A sigmoidal Emax relationship was identified between concizumab 
plasma concentration and peak thrombin generation potential in 
EXPLORER3 (Figure 3). A number of observations of peak thrombin 
generation within the normal range were noted at low concizumab 
levels, potentially representing the effect of residual FVIII, which, 
in theory, could be either through secondary missense mutations 
or due to the long terminal half‐life of administered FVIII. Since 
these observations constitute a considerable part of the residual 
variability, more detailed effects, such as random effects, were not 
investigated. The estimated typical EC50 value (ie, the concizumab 
concentration predicted to give 50% of the maximum possible effect 
on peak thrombin generation) was 63 ng/mL.
There was a strong correlation between concizumab concen‐
tration and peak thrombin generation potential in data collected in 
EXPLORER3, with concizumab >100 ng/mL re‐establishing throm‐
bin generation potential within a normal range (60‐130 nmol/L) 
(Figure 4). Median (interquartile range [IQR]) peak thrombin was 15 
(10‐24), 31.5 (17.25‐61) and 81 (65.5‐100) nmol/L for concizumab 
≤20, >20 to ≤100 and >100 ng/mL, respectively.
3.3 | Concizumab exposure‐bleeding episode 
association
As EXPLORER3 was not an efficacy trial, a prophylactic effect of 
concizumab administration in terms of bleeding events could not be 
assessed. However, a correlation between the frequency of bleed‐
ing episodes and concizumab concentration was indicated, with 
fewer bleeds observed at concizumab concentrations >100 ng/
mL and at free TFPI levels <25% relative to baseline (Figure 2). It 
should be noted that there was substantially less exposure time 
with concizumab concentrations above 100 ng/mL vs those below 
100 ng/mL.
4  | DISCUSSION
In PK/PD analyses of EXPLORER3 data, it was noted that at con‐
cizumab exposure levels >100 ng/mL, the thrombin generation 
potential was re‐established to predominantly within the normal 
range. Additionally, results from PK/PD analyses of concizumab 
phase 1/1b data indicated a clinically relevant prophylactic effect 
for haemophilia patients at concizumab exposure levels >100 ng/
mL, based on the decrease in reported bleeding episodes noted at 
estimated concizumab exposure above that level. The PK/PD results 
obtained were consistent across all concizumab phase 1/1b trials. 
Based on these results, the concizumab phase 2 clinical develop‐
ment programme has been designed to target a concizumab expo‐
sure of at least 100 ng/mL. In addition, a once‐daily, efficacy‐based, 
individual, dose‐escalation regimen has been selected for the phase 
2 trials with the aim of reducing PK variability (previously noted in 
the highest dose cohort in EXPLORER3, receiving 0.8 mg/kg, once 
every 4 days).16 The results from the current PK/PD analyses should 
be considered in the light of the fact that patients had not been rand‐
omized to concizumab exposure/dose, which represents a limitation 
when conducting exposure‐response analyses.
In EXPLORER4, patients with haemophilia A or B with in‐
hibitors will receive a loading dose of concizumab 0.5 mg/kg as 
the first dose, followed by 0.15 mg/kg (sc, daily), with potential 
F I G U R E  3   Concizumab plasma concentration and peak 
thrombin generation potential in EXPLORER3. Peak thrombin 
generation vs concizumab concentration based on observations 
in the EXPLORER3 trial for the three concizumab doses tested 
(0.25, 0.5 and 0.8 mg/kg) are shown, excluding data obtained 
≤72 h following factor VIII administration. The solid line represents 
predictions from an Emax model in which the peak thrombin 
generation logarithm was fitted with concizumab concentration 
as explanatory variable. The dotted horizontal lines indicate the 
normal range of thrombin generation potential (60‐130 nmol/L)
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F I G U R E  4   Correlation between concizumab concentration and 
peak thrombin generation in EXPLORER3. Based on all EXPLORER3 
data for which simultaneously collected concizumab and peak 
thrombin generation samples were available. Observations 
excluding data ≤72 h following factor VIII administration due to 
bleeding events are shown. Peak thrombin is shown as individual 
values and medians (central horizontal line) with interquartile 
ranges (error bars). The dotted horizontal lines indicate the normal 
range of thrombin generation potential (60‐130 nmol/L)
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stepwise dose escalation to 0.25 mg/kg in case of recurrent 
bleeds. In the EXPLORER5 trial, patients with severe haemophilia 
A without inhibitors will receive concizumab 0.15 mg/kg (sc, 
daily), with potential stepwise dose administration to 0.25 mg/
kg in case of recurrent bleeds. For a typical subject, Ctrough values 
of 140, 250 and 440 ng/mL are expected with concizumab 0.15, 
0.20 and 0.25 mg/kg daily, respectively. Additional data from 
these phase 2 trials will help fine‐tune the therapeutic window 
for concizumab in different populations of haemophilia patients. 
They will also provide a larger data set and results based on a 
longer exposure to concizumab, thus expanding the scope of the 
current analyses.
Our analyses showed a strong correlation between concizumab 
exposure and free TFPI. The estimated typical EC50 values for con‐
cizumab‐free TFPI and concizumab‐thrombin generation were very 
similar (62 and 63 ng/mL, respectively), a result that supports free 
TFPI (ie, TFPI in plasma, not bound to concizumab) as a useful bio‐
marker for concizumab efficacy. Moreover, there was an indication 
of fewer bleeds at lower free TFPI concentrations.
There are several advantages associated with the use of conci‐
zumab for the treatment of patients with haemophilia. As previously 
noted, its unique mechanism of action renders it applicable for both 
haemophilia A and B patients, both with or without inhibitors. As a sc 
therapeutic, treatment with concizumab should result in a significant 
improvement in compliance in terms of prophylaxis and therefore 
lead to improved treatment outcomes, including in patients with se‐
vere haemophilia, in whom prophylactic treatment is recommended 
and can help maintain normal musculoskeletal function.1 An addi‐
tional advantage associated with concizumab is its availability as a 
liquid formulation with a long shelf‐life that can be easily adminis‐
tered at small volumes via a portable pen device stored at room tem‐
perature. In a small pen injector handling test among haemophilia 
patients accustomed to using syringe‐to‐vial systems, a positive re‐
sponse to the pen device was noted, with no handling difficulties or 
errors documented.11 Crucially, as concizumab is a mAb, there is no 
risk of developing inhibitors towards coagulation factors, the most 
significant complication associated with factor replacement treat‐
ment.2‐4 Finally, and of note, no neutralizing anti‐drug antibodies 
were observed following treatment with concizumab in any of the 
phase 1/1b trials.
5  | CONCLUSION
Based on the results of the PK/PD analyses presented herein, 
the phase 2 concizumab clinical development programme has 
been designed to target an exposure of at least 100 ng/mL, and 
a once‐daily, efficacy‐based, individual dose‐escalation regimen 
has been selected to reduce exposure variability. The minimum 
concizumab exposure level required to achieve sufficient hae‐
mostatic efficacy will be fine‐tuned following the availability of 
phase 2 clinical data.
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